Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed Phase 1 Interventional

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

NCT01856426
View directory record Official record
Conditions
Hepatitis C
Interventions
EDP239, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT00952263
View directory record Official record
Conditions
Healthy
Interventions
MBL-HCV1
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

NCT00047814
View directory record Official record
Conditions
Hepatitis C
Interventions
FK788
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
9
States / cities
Pasadena, California • Lakewood, Colorado • Gainsville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

NCT00752687
View directory record Official record
Conditions
Hepatitis C
Interventions
ABT-072, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

NCT00018031
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 23, 2026, 5:41 PM EDT
Completed No phase listed Observational

Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers

NCT00342641
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
815,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

NCT00447902
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes

NCT00324389
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon alpha
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

NCT03420768
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis
Interventions
BMS-986263, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 23, 2026, 5:41 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Alcohol-Related Hepatitis With Arginine

NCT00200746
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Arginine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Hepatitis C Translating Initiatives for Depression Into Effective Solutions

NCT01143896
View directory record Official record
Conditions
Hepatitis C, Depression
Interventions
Depression collaborative care model
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Little Rock, Arkansas • West Los Angeles, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

NCT00458393
View directory record Official record
Conditions
HIV Infections
Interventions
daily TDF/FTC, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 3 Interventional

Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B

NCT00115245
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Telbivudine (LdT), Adefovir Dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 23, 2026, 5:41 PM EDT
Completed No phase listed Observational

Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure

NCT02737345
View directory record Official record
Conditions
Cirrhosis
Interventions
Rotem
Other
Lead sponsor
Scott Allen
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

NCT02556372
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
JKB-122
Drug
Lead sponsor
TaiwanJ Pharmaceuticals Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

NCT00662545
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

NCT02631772
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 23, 2026, 5:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Reducing Depressive Symptoms During HCV Therapy: A Randomized Study

NCT00495768
View directory record Official record
Conditions
Hepatitis C, Depression
Interventions
Group Training
Behavioral
Lead sponsor
South Texas Veterans Health Care System
Federal
Eligibility
25 Years to 68 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2007 · Synced Oct 23, 2026, 5:41 PM EDT
Approved For Marketing No phase listed Expanded access

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

NCT01198860
View directory record Official record
Conditions
CHRONIC HEPATITIS B
Interventions
CTH Chronic Hepatitis B
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 5:41 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study

NCT00637520
View directory record Official record
Conditions
Insulin Resistance, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 23, 2026, 5:41 PM EDT
Withdrawn No phase listed Observational

Immunology of HIV and Alcoholic Hepatitis

NCT03951662
View directory record Official record
Conditions
HIV/AIDS, Alcoholic Hepatitis
Interventions
Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 23, 2026, 5:41 PM EDT